% $ biblatex auxiliary file $
% $ biblatex version 1.7 $
% Do not modify the above lines!
%
% This is an auxiliary file used by the 'biblatex' package.
% This file may safely be deleted. It will be recreated as
% required.
%
\begingroup
\makeatletter
\@ifundefined{ver@biblatex.sty}
  {\@latex@error
     {Missing 'biblatex' package}
     {The bibliography requires the 'biblatex' package.}
      \aftergroup\endinput}
  {}
\endgroup

\entry{Georgiev2013a}{article}{}
  \name{author}{25}{}{%
    {{}%
     {Georgiev}{G.}%
     {Ivelin~S.}{I.~S.}%
     {}{}%
     {}{}}%
    {{}%
     {Doria-Rose}{D.-R.}%
     {Nicole~A.}{N.~A.}%
     {}{}%
     {}{}}%
    {{}%
     {Zhou}{Z.}%
     {Tongqing}{T.}%
     {}{}%
     {}{}}%
    {{}%
     {Kwon}{K.}%
     {Young~Do}{Y.~D.}%
     {}{}%
     {}{}}%
    {{}%
     {Staupe}{S.}%
     {Ryan~P.}{R.~P.}%
     {}{}%
     {}{}}%
    {{}%
     {Moquin}{M.}%
     {Stephanie}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Chuang}{C.}%
     {Gwo-Yu}{G.-Y.}%
     {}{}%
     {}{}}%
    {{}%
     {Louder}{L.}%
     {Mark~K.}{M.~K.}%
     {}{}%
     {}{}}%
    {{}%
     {Schmidt}{S.}%
     {Stephen~D.}{S.~D.}%
     {}{}%
     {}{}}%
    {{}%
     {Altae-Tran}{A.-T.}%
     {Han~R.}{H.~R.}%
     {}{}%
     {}{}}%
    {{}%
     {Bailer}{B.}%
     {Robert~T.}{R.~T.}%
     {}{}%
     {}{}}%
    {{}%
     {McKee}{M.}%
     {Krisha}{K.}%
     {}{}%
     {}{}}%
    {{}%
     {Nason}{N.}%
     {Martha}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {O'Dell}{O.}%
     {Sijy}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Ofek}{O.}%
     {Gilad}{G.}%
     {}{}%
     {}{}}%
    {{}%
     {Pancera}{P.}%
     {Marie}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Srivatsan}{S.}%
     {Sanjay}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Shapiro}{S.}%
     {Lawrence}{L.}%
     {}{}%
     {}{}}%
    {{}%
     {Connors}{C.}%
     {Mark}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Migueles}{M.}%
     {Stephen~A.}{S.~A.}%
     {}{}%
     {}{}}%
    {{}%
     {Morris}{M.}%
     {Lynn}{L.}%
     {}{}%
     {}{}}%
    {{}%
     {Nishimura}{N.}%
     {Yoshiaki}{Y.}%
     {}{}%
     {}{}}%
    {{}%
     {Martin}{M.}%
     {Malcolm~A.}{M.~A.}%
     {}{}%
     {}{}}%
    {{}%
     {Mascola}{M.}%
     {John~R.}{J.~R.}%
     {}{}%
     {}{}}%
    {{}%
     {Kwong}{K.}%
     {Peter~D.}{P.~D.}%
     {}{}%
     {}{}}%
  }
  \keyw{Animals; Antibodies, Neutralizing, blood/immunology; Epitope Mapping;
  HIV Antibodies, blood/immunology; HIV Infections, blood/immunology; HIV-1,
  immunology/isolation /&/ purification; Humans; Immunodominant Epitopes,
  chemistry/immunology; Macaca; Neutralization Tests; Protein Conformation;
  Serum, immunology}
  \strng{namehash}{GIS+1}
  \strng{fullhash}{GISDRNAZTKYDSRPMSCGYLMKSSDATHRBRTMKNMOSOGPMSSSLCMMSAMLNYMMAMJRKPD1}
  \field{abstract}{%
  Serum characterization and antibody isolation are transforming our
  understanding of the humoral immune response to viral infection. Here, we
  show that epitope specificities of HIV-1-neutralizing antibodies in serum can
  be elucidated from the serum pattern of neutralization against a diverse
  panel of HIV-1 isolates. We determined "neutralization fingerprints" for 30
  neutralizing antibodies on a panel of 34 diverse HIV-1 strains and showed
  that similarity in neutralization fingerprint correlated with similarity in
  epitope. We used these fingerprints to delineate specificities of polyclonal
  sera from 24 HIV-1-infected donors and a chimeric siman-human
  immunodeficiency virus-infected macaque. Delineated specificities matched
  published specificities and were further confirmed by antibody isolation for
  two sera. Patterns of virus-isolate neutralization can thus afford a detailed
  epitope-specific understanding of neutralizing-antibody responses to viral
  infection.%
  }
  \verb{doi}
  \verb 10.1126/science.1233989
  \endverb
  \field{number}{6133}
  \field{pages}{751\bibrangedash 756}
  \field{title}{Delineating antibody recognition in polyclonal sera from
  patterns of HIV-1 isolate neutralization.}
  \verb{url}
  \verb http://dx.doi.org/10.1126/science.1233989
  \endverb
  \field{volume}{340}
  \field{journaltitle}{Science}
  \field{year}{2013}
  \warn{\item Invalid format of field 'month'}
\endentry

\entry{Kirchherr2011}{article}{}
  \name{author}{16}{}{%
    {{}%
     {Kirchherr}{K.}%
     {Jennifer~L.}{J.~L.}%
     {}{}%
     {}{}}%
    {{}%
     {Hamilton}{H.}%
     {Jennifer}{J.}%
     {}{}%
     {}{}}%
    {{}%
     {Lu}{L.}%
     {Xiaozhi}{X.}%
     {}{}%
     {}{}}%
    {{}%
     {Gnanakaran}{G.}%
     {S.}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Muldoon}{M.}%
     {Mark}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Daniels}{D.}%
     {Marcus}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Kasongo}{K.}%
     {Webster}{W.}%
     {}{}%
     {}{}}%
    {{}%
     {Chalwe}{C.}%
     {Victor}{V.}%
     {}{}%
     {}{}}%
    {{}%
     {Mulenga}{M.}%
     {Chanda}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Mwananyanda}{M.}%
     {Lawrence}{L.}%
     {}{}%
     {}{}}%
    {{}%
     {Musonda}{M.}%
     {Rosemary~M.}{R.~M.}%
     {}{}%
     {}{}}%
    {{}%
     {Yuan}{Y.}%
     {Xing}{X.}%
     {}{}%
     {}{}}%
    {{}%
     {Montefiori}{M.}%
     {David~C.}{D.~C.}%
     {}{}%
     {}{}}%
    {{}%
     {Korber}{K.}%
     {Bette~T.}{B.~T.}%
     {}{}%
     {}{}}%
    {{}%
     {Haynes}{H.}%
     {Barton~F.}{B.~F.}%
     {}{}%
     {}{}}%
    {{}%
     {Gao}{G.}%
     {Feng}{F.}%
     {}{}%
     {}{}}%
  }
  \keyw{Adult; Amino Acid Substitution, genetics; Antibodies, Neutralizing,
  immunology; Cross Reactions; Epitopes, genetics/immunology; Female; HIV
  Antibodies, immunology; HIV Envelope Protein gp120, genetics/immunology;
  HIV-1, genetics/immunology; Humans; Male; Middle Aged; Molecular Sequence
  Data; Neutralization Tests; Sequence Analysis, DNA}
  \strng{namehash}{KJL+1}
  \strng{fullhash}{KJLHJLXGSMMDMKWCVMCMLMRMYXMDCKBTHBFGF1}
  \field{abstract}{%
  Neutralizing antibodies (Nabs) are thought to play an important role in
  prevention and control of HIV-1 infection and should be targeted by an AIDS
  vaccine. It is critical to understand how HIV-1 induces Nabs by analyzing
  viral sequences in both tested viruses and sera. Neutralization
  susceptibility to antibodies in autologous and heterologous plasma was
  determined for multiple Envs (3-6) from each of 15 subtype-C-infected
  individuals. Heterologous neutralization was divided into two distinct
  groups: plasma with strong, cross-reactive neutralization (n=9) and plasma
  with weak neutralization (n=6). Plasma with cross-reactive heterologous Nabs
  also more potently neutralized contemporaneous autologous viruses. Analysis
  of Env sequences in plasma from both groups revealed a three-amino-acid
  substitution pattern in the V4 region that was associated with greater
  neutralization potency and breadth. Identification of such potential
  neutralization signatures may have important implications for the development
  of HIV-1 vaccines capable of inducing Nabs to subtype C HIV-1.%
  }
  \verb{doi}
  \verb 10.1016/j.virol.2010.09.031
  \endverb
  \field{number}{2}
  \field{pages}{163\bibrangedash 174}
  \field{title}{Identification of amino acid substitutions associated with
  neutralization phenotype in the human immunodeficiency virus type-1 subtype C
  gp120.}
  \verb{url}
  \verb http://dx.doi.org/10.1016/j.virol.2010.09.031
  \endverb
  \field{volume}{409}
  \field{journaltitle}{Virology}
  \field{year}{2011}
  \warn{\item Invalid format of field 'month'}
\endentry

\entry{Oh2001}{article}{}
  \name{author}{2}{}{%
    {{}%
     {Oh}{O.}%
     {Man-Suk}{M.-S.}%
     {}{}%
     {}{}}%
    {{}%
     {Raftery}{R.}%
     {Adrian~E}{A.~E.}%
     {}{}%
     {}{}}%
  }
  \list{publisher}{1}{%
    {Taylor \& Francis}%
  }
  \strng{namehash}{OMSRAE1}
  \strng{fullhash}{OMSRAE1}
  \field{number}{455}
  \field{pages}{1031\bibrangedash 1044}
  \field{title}{Bayesian multidimensional scaling and choice of dimension}
  \field{volume}{96}
  \field{journaltitle}{JASA}
  \field{year}{2001}
\endentry

\entry{Ping2013}{article}{}
  \name{author}{40}{}{%
    {{}%
     {Ping}{P.}%
     {Li-Hua}{L.-H.}%
     {}{}%
     {}{}}%
    {{}%
     {Joseph}{J.}%
     {Sarah~B.}{S.~B.}%
     {}{}%
     {}{}}%
    {{}%
     {Anderson}{A.}%
     {Jeffrey~A.}{J.~A.}%
     {}{}%
     {}{}}%
    {{}%
     {Abrahams}{A.}%
     {Melissa-Rose}{M.-R.}%
     {}{}%
     {}{}}%
    {{}%
     {Salazar-Gonzalez}{S.-G.}%
     {Jesus~F.}{J.~F.}%
     {}{}%
     {}{}}%
    {{}%
     {Kincer}{K.}%
     {Laura~P.}{L.~P.}%
     {}{}%
     {}{}}%
    {{}%
     {Treurnicht}{T.}%
     {Florette~K.}{F.~K.}%
     {}{}%
     {}{}}%
    {{}%
     {Arney}{A.}%
     {Leslie}{L.}%
     {}{}%
     {}{}}%
    {{}%
     {Ojeda}{O.}%
     {Suany}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Zhang}{Z.}%
     {Ming}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Keys}{K.}%
     {Jessica}{J.}%
     {}{}%
     {}{}}%
    {{}%
     {Potter}{P.}%
     {E~Lake}{E.~L.}%
     {}{}%
     {}{}}%
    {{}%
     {Chu}{C.}%
     {Haitao}{H.}%
     {}{}%
     {}{}}%
    {{}%
     {Moore}{M.}%
     {Penny}{P.}%
     {}{}%
     {}{}}%
    {{}%
     {Salazar-Gonzalez}{S.-G.}%
     {Maria}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Iyer}{I.}%
     {Shilpa}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Jabara}{J.}%
     {Cassandra}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Kirchherr}{K.}%
     {Jennifer}{J.}%
     {}{}%
     {}{}}%
    {{}%
     {Mapanje}{M.}%
     {Clement}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Ngandu}{N.}%
     {Nobubelo}{N.}%
     {}{}%
     {}{}}%
    {{}%
     {Seoighe}{S.}%
     {Cathal}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Hoffman}{H.}%
     {Irving}{I.}%
     {}{}%
     {}{}}%
    {{}%
     {Gao}{G.}%
     {Feng}{F.}%
     {}{}%
     {}{}}%
    {{}%
     {Tang}{T.}%
     {Yuyang}{Y.}%
     {}{}%
     {}{}}%
    {{}%
     {Labranche}{L.}%
     {Celia}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Lee}{L.}%
     {Benhur}{B.}%
     {}{}%
     {}{}}%
    {{}%
     {Saville}{S.}%
     {Andrew}{A.}%
     {}{}%
     {}{}}%
    {{}%
     {Vermeulen}{V.}%
     {Marion}{M.}%
     {}{}%
     {}{}}%
    {{}%
     {Fiscus}{F.}%
     {Susan}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Morris}{M.}%
     {Lynn}{L.}%
     {}{}%
     {}{}}%
    {{}%
     {{Abdool Karim}}{A.}%
     {Salim}{S.}%
     {}{}%
     {}{}}%
    {{}%
     {Haynes}{H.}%
     {Barton~F.}{B.~F.}%
     {}{}%
     {}{}}%
    {{}%
     {Shaw}{S.}%
     {George~M.}{G.~M.}%
     {}{}%
     {}{}}%
    {{}%
     {Korber}{K.}%
     {Bette~T.}{B.~T.}%
     {}{}%
     {}{}}%
    {{}%
     {Hahn}{H.}%
     {Beatrice~H.}{B.~H.}%
     {}{}%
     {}{}}%
    {{}%
     {Cohen}{C.}%
     {Myron~S.}{M.~S.}%
     {}{}%
     {}{}}%
    {{}%
     {Montefiori}{M.}%
     {David}{D.}%
     {}{}%
     {}{}}%
    {{}%
     {Williamson}{W.}%
     {Carolyn}{C.}%
     {}{}%
     {}{}}%
    {{}%
     {Swanstrom}{S.}%
     {Ronald}{R.}%
     {}{}%
     {}{}}%
    {{}%
     {}{}%
     {for the C. A. P. R. I. S. A Acute Infection Study the Center for H. I.
  V-A. I. D. S Vaccine Immunology~Consortium}{f.~t. C. A. P. R. I. S. A. A. I.
  S. t. C. f. H. I. V.-A. I. D. S. V. I.~C.}%
     {}{}%
     {}{}}%
  }
  \strng{namehash}{PLH+1}
  \strng{fullhash}{PLHJSBAJAAMRSGJFKLPTFKALOSZMKJPELCHMPSGMISJCKJMCNNSCHIGFTYLCLBSAVMFSMLASHBFSGMKBTHBHCMSMDWCSRftCAPRISAAIStCfHIVAIDSVIC1}
  \field{abstract}{%
  Understanding human immunodeficiency virus type 1 (HIV-1) transmission is
  central to developing effective prevention strategies, including a vaccine.
  We compared phenotypic and genetic variation in HIV-1 env genes from subjects
  in acute/early infection to subjects with chronic infections in the context
  of subtype C heterosexual transmission. We found that the transmitted viruses
  all used CCR5 and required high levels of CD4 to infect target cells,
  suggesting selection for replication in T cells after transmission and not
  macrophages. In addition, the transmitted viruses were more likely to use a
  maraviroc-sensitive conformation of CCR5, perhaps identifying a feature of
  the target T cell. We confirmed an earlier observation that the transmitted
  viruses were on average modestly under-glycosylated relative to the viruses
  from chronically infected subjects. This difference was most pronounced in
  comparing the viruses in acutely infected men to those in chronically
  infected women. These features of the transmitted virus point to selective
  pressures during the transmission event. We did not observe a consistent
  difference in heterologous neutralization sensitivity between the two groups,
  or in sensitivity to soluble CD4, suggesting similar conformations between
  viruses from acute and chronic infection. However, the presence or absence of
  glycosylation sites had differential effects on neutralization sensitivity
  for different antibodies. We suggest that the occasional absence of
  glycosylation sites encoded in the conserved regions of env, further reduced
  in transmitted viruses, could expose specific surface structures on the
  protein as antibody targets.%
  }
  \field{title}{Comparison of Viral Env Proteins From Acute and Chronic
  Infections of Subtype C Human Immunodeficiency Virus Type 1 Identifies
  Differences In Glycosylation and CCR5 Utilization and Suggests A New Strategy
  For Immunogen Design.}
  \field{journaltitle}{J Virol}
  \field{year}{2013}
  \warn{\item Invalid format of field 'month'}
\endentry

\entry{vanGils2010}{article}{}
  \name{author}{5}{}{%
    {{}%
     {{van Gils}}{v.}%
     {Marit~J.}{M.~J.}%
     {}{}%
     {}{}}%
    {{}%
     {Edo-Matas}{E.-M.}%
     {Diana}{D.}%
     {}{}%
     {}{}}%
    {{}%
     {Schweighardt}{S.}%
     {Becky}{B.}%
     {}{}%
     {}{}}%
    {{}%
     {Wrin}{W.}%
     {Terri}{T.}%
     {}{}%
     {}{}}%
    {{}%
     {Schuitemaker}{S.}%
     {Hanneke}{H.}%
     {}{}%
     {}{}}%
  }
  \keyw{Antibodies, Neutralizing, blood/immunology; Cross Reactions; HIV
  Antibodies, blood/immunology; HIV Infections, immunology; HIV-1, immunology;
  Humans; Inhibitory Concentration 50; Netherlands; Neutralization Tests}
  \strng{namehash}{vMJ+1}
  \strng{fullhash}{vMJEMDSBWTSH1}
  \field{abstract}{%
  It is assumed that an effective human immunodeficiency virus type 1 (HIV-1)
  vaccine should be capable of eliciting neutralizing antibodies. However, even
  the best antibodies known to date lack neutralizing ability against a
  significant proportion of primary HIV-1 variants and, despite great efforts,
  still no immunogen is available that can elicit humoral immunity which is
  protective against infection or disease progression. We tested sera from 35
  participants in the Amsterdam Cohort Studies on HIV-1 infection, who were all
  infected with HIV-1 subtype B and therapy-na√Øve at the time of sampling, for
  neutralizing activity against a panel of 23 tier 2-3 HIV-1 variants, with a
  minimum of five HIV-1 variants per subtype (A, B, C and D). Strong
  cross-clade neutralizing activity was detected in sera from seven
  individuals. Strikingly, sera from 22 of 35 individuals (63\%) neutralized
  three or more of the six tier 2-3 HIV-1 subtype B viruses in the panel. There
  was a strong correlation between neutralization titre and breadth in serum.
  Indeed, the IC(50) of sera with strong cross-clade neutralizing activity was
  significantly higher than the IC(50) of sera with cross-subtype B activity,
  which, in turn, had a higher IC(50) than sera with the lowest neutralization
  breadth. These results imply that humoral immunity, at least in HIV-1 subtype
  B-infected individuals, is often subtype-specific rather than strain-specific
  and that the breadth of neutralization is correlated with the titre of
  neutralizing activity in serum. Considering the difficulties in designing a
  vaccine that is capable of eliciting cross-clade neutralizing activity,
  subtype-specific vaccines may be explored as an interesting alternative.%
  }
  \verb{doi}
  \verb 10.1099/vir.0.015693-0
  \endverb
  \field{number}{Pt 1}
  \field{pages}{250\bibrangedash 258}
  \field{title}{High prevalence of neutralizing activity against multiple
  unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in
  sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific
  rather than strain-specific neutralizing activity.}
  \verb{url}
  \verb http://dx.doi.org/10.1099/vir.0.015693-0
  \endverb
  \field{volume}{91}
  \field{journaltitle}{J Gen Virol}
  \field{year}{2010}
  \warn{\item Invalid format of field 'month'}
\endentry

\lossort
\endlossort

\endinput
